收费全文 | 5987篇 |
免费 | 508篇 |
国内免费 | 18篇 |
耳鼻咽喉 | 17篇 |
儿科学 | 127篇 |
妇产科学 | 124篇 |
基础医学 | 1024篇 |
口腔科学 | 35篇 |
临床医学 | 640篇 |
内科学 | 1201篇 |
皮肤病学 | 128篇 |
神经病学 | 677篇 |
特种医学 | 131篇 |
外科学 | 511篇 |
综合类 | 24篇 |
一般理论 | 3篇 |
预防医学 | 551篇 |
眼科学 | 87篇 |
药学 | 574篇 |
中国医学 | 11篇 |
肿瘤学 | 648篇 |
2023年 | 54篇 |
2022年 | 42篇 |
2021年 | 172篇 |
2020年 | 103篇 |
2019年 | 182篇 |
2018年 | 192篇 |
2017年 | 121篇 |
2016年 | 163篇 |
2015年 | 178篇 |
2014年 | 243篇 |
2013年 | 339篇 |
2012年 | 516篇 |
2011年 | 479篇 |
2010年 | 281篇 |
2009年 | 207篇 |
2008年 | 407篇 |
2007年 | 429篇 |
2006年 | 381篇 |
2005年 | 339篇 |
2004年 | 354篇 |
2003年 | 311篇 |
2002年 | 277篇 |
2001年 | 43篇 |
2000年 | 34篇 |
1999年 | 55篇 |
1998年 | 51篇 |
1997年 | 43篇 |
1996年 | 32篇 |
1995年 | 30篇 |
1994年 | 19篇 |
1993年 | 24篇 |
1992年 | 21篇 |
1991年 | 14篇 |
1990年 | 22篇 |
1989年 | 28篇 |
1988年 | 18篇 |
1987年 | 17篇 |
1986年 | 9篇 |
1985年 | 23篇 |
1984年 | 12篇 |
1983年 | 12篇 |
1982年 | 19篇 |
1981年 | 13篇 |
1980年 | 8篇 |
1979年 | 16篇 |
1978年 | 12篇 |
1970年 | 7篇 |
1969年 | 11篇 |
1965年 | 7篇 |
1963年 | 7篇 |
Methods: A systematic literature search was performed to identify relevant randomized controlled trials (RCTs). Key outcomes of interest were clinical response (CD activity index [CDAI] reduction of 100 points; CDAI-100) and remission (CDAI score under 150 points; CDAI < 150). A treatment sequence Bayesian NMA was conducted to account for the re-randomization of patients based on different clinical definitions, the lack of similarity of the common comparator for each trial and the full treatment pathway from the induction phase onwards.
Results: Thirteen RCTs were identified. Ustekinumab 90?mg q8w was associated with statistically significant improvement in clinical response relative to placebo and vedolizumab 300?mg. For clinical remission, ustekinumab 90?mg q8w was associated with statistically significant improvement relative to placebo and vedolizumab 300?mg q8w. Findings from sub-population analyses had similar results but were not statistically significant.
Conclusions: The NMA suggest that ustekinumab is associated with the highest likelihood of reaching response or remission at 1?year compared with placebo, adalimumab and vedolizumab. Results should be interpreted with caution because this is a novel methodology; however, the treatment sequence analysis may be the most methodologically sound analysis to derive estimates of comparative efficacy in CD in the absence of head-to-head evidence. 相似文献
Background
Two electrochemiluminescence (ECL) assays were developed which, together, can simultaneously measure serum antibodies against pneumococcal capsular polysaccharides (PnPS) for 17 serotypes. The assays were validated for the 13 PnPS included in the 13-valent pneumococcal conjugate vaccine (PCV13). As recommended by the World Health Organization (WHO), we compared the ECL assays with the WHO reference enzyme-linked immunosorbent assay (ELISA) and derived a threshold corresponding to the 0.35?µg/mL threshold established for the WHO reference ELISA for the non-inferiority comparison and licensure of new PCVs against invasive pneumococcal disease.Methods
A panel of 452 serum samples from children vaccinated with one of the three licensed PCVs was assessed with the ECL assays and the WHO reference ELISA. The ECL assay threshold for the aggregated seven PnPS included in the 7-valent PCV (PCV7) and serotype-specific thresholds were determined using a receiver operating characteristics (ROC) curve-based approach and Deming regression. To evaluate concordance between the ECL assays and the WHO reference ELISA, serostatus agreement rates between both assays and geometric means of the ratios (GMRs) of concentrations obtained with both assays were calculated.Results
The thresholds for the seven aggregated PCV7 serotypes obtained with the ROC curve-based approach and Deming regression approximated 0.35?µg/mL (0.38 and 0.34?µg/mL, respectively). Individual thresholds for the PCV13 serotypes ranged between 0.24 and 0.51?µg/mL across both approaches. Serostatus agreement rates using a 0.35?µg/mL threshold for both assays were ≥86.9% for all PCV13 serotypes. GMRs ranged between 0.85 and 1.25 for 11/13 serotypes and were <1.29 for the two remaining serotypes.Conclusion
The ECL assays were comparable to the WHO reference ELISA and offer a sensitive, time- and serum volume-saving method to quantify serotype-specific anti-PnPS antibodies in pediatric sera. A 0.35?µg/mL threshold will be used for each PCV13 serotype to assess PCV immunogenicity in clinical trials. 相似文献Methods: We performed a systematic review of all available publications and extracted data from national and international guidelines. The Task Force evaluated the data with respect to the strength of evidence for the efficacy and safety of each medication.
Results and Discussion: There is no safe level of alcohol use during pregnancy. Abstinence is recommended. Ideally, women should stop alcohol use when pregnancy is planned and, in any case, as soon as pregnancy is known. Detecting patterns of alcohol maternal drinking should be systematically conducted at first antenatal visit and throughout pregnancy. Brief interventions are recommended in the case of low or moderate risk of alcohol use. Low doses of benzodiazepines, for the shortest duration, may be used to prevent alcohol withdrawal symptoms when high and chronic alcohol intake is stopped and hospitalisation is recommended. Due to the low level of evidence and/or to low benefit/risk ratio, pharmacological treatment for maintenance of abstinence should not be used during pregnancy. At birth, foetal alcohol spectrum disorders must be searched for, and alcohol metabolites should be measured in meconium of neonates in any doubt of foetal alcohol exposure. 相似文献